What Is DAC in Peptides? Albumin Binding

If you are asking what is dac in peptides, DAC means Drug Affinity Complex: a maleimide-bearing linker that lets a peptide form a covalent bond with albumin at cysteine 34 (Cys34). The carrier slows clearance, stretching exposure from minutes toward days in CJC-1295. DAC changes pharmacokinetics, not proof that the peptide improves health or performance.

What does DAC actually add to a peptide?

DAC adds a chemical hook, not a new biological target. A drug affinity complex peptide combines the active peptide with a linker and a maleimide group. In blood, that maleimide reacts with albumin’s free Cys34 thiol, creating a stable covalent attachment. Think of a small parcel clipping itself to a long-haul truck instead of traveling alone.

Albumin is large and stays in circulation far longer than a free short peptide. Attachment can reduce rapid kidney clearance and shield the peptide from some enzymatic breakdown. The original CJC-1295 work describes a C-terminal lysine carrying a maleimide-containing group; rat plasma showed an albumin-sized CJC-1295 signal within 15 minutes and beyond 24 hours (Jetté et al., 2005). That is direct preclinical evidence for the mechanism, not a human outcome trial.

DAC is therefore one answer to a general engineering problem: how do you stop a useful peptide disappearing before it can do much? Our guide to peptide half-life explains the clearance math behind that question.

What did the CJC-1295 human trial prove?

CJC-1295 with DAC lasted for days and raised growth hormone (GH) and insulin-like growth factor 1 (IGF-1) in healthy adults. In two randomized, placebo-controlled, double-blind, ascending-dose trials, researchers estimated a 5.8-to-8.1-day half-life. After one injection, mean GH rose for at least six days and mean IGF-1 for nine to 11 days (Teichman et al., 2006).

That human evidence tier is strong for pharmacokinetics and hormone markers. The trial did not test muscle gain, fat loss, recovery, longevity, or any patient-centered treatment benefit. “Half-life measured in humans” and “health benefit demonstrated in humans” belong on different evidence shelves. Vendor pages tend to shelve them together because the second claim sells better.

The CJC-1295 profile separates those endpoints. The study also examined the DAC form; its 5.8-to-8.1-day number cannot be pasted onto a vial labeled no DAC.

Is CJC-1295 with DAC vs no DAC a clean comparison?

CJC-1295 with DAC vs no DAC is a useful shorthand, but the names are not reliably clean chemical identities. Published CJC-1295 is the albumin-binding DAC construct. Online sellers commonly use “CJC-1295 without DAC” for modified GRF 1-29, the stabilized GHRH fragment without the albumin hook.

The directional difference is sound: the DAC construct covalently attaches to albumin and persists for days; the no-DAC peptide lacks that extension. The exact no-DAC human half-life is not established by the Teichman trial. A label that says only “CJC-1295” also leaves a basic question unanswered: which molecule is in the vial?

This naming problem matters beyond semantics. Half-life, exposure pattern, evidence, and analytical identity all change with the modification. “With DAC” is chemistry. It is not a quality grade, potency badge, or promise that the material matches a studied product.

How can you decode other half-life-extension labels?

Half-life-extension labels usually reveal which carrier strategy a drug uses: permanent albumin attachment, reversible albumin binding, or fusion to a long-lived protein domain. Once you identify the strategy, ask whether the bond is covalent, what molecule was studied, and whether the quoted half-life came from humans using the same route and formulation.

Label or example	What was added	What the label tells you
DAC / CJC-1295	Maleimide-bearing linker	Covalent attachment to albumin Cys34
Peptide acylation / semaglutide and liraglutide	Fatty-acid side chain plus linker	Reversible albumin binding; not DAC chemistry
Fc fusion / dulaglutide	Modified immunoglobulin G4 Fc domain	A much larger fusion protein, not an albumin-bound peptide

Semaglutide shows why the distinction is useful. Its design paper says the fatty-acid moiety and linker were tuned for high albumin affinity and prolonged exposure (Lau et al., 2015). That is peptide acylation: albumin binding half-life extension without a covalent Cys34 bond.

Dulaglutide takes another route. The current DailyMed label describes two GLP-1 analog chains linked to a modified IgG4 Fc portion, with an overall molecular weight near 63 kilodaltons and an elimination half-life of about five days. Same engineering goal, different machine under the hood.

Does a longer half-life mean a better peptide?

A longer half-life means longer exposure, not automatically better results. The change may widen dosing intervals and smooth concentration swings, but it can also prolong unwanted effects and make rapid washout impossible. Receptor activity, tissue access, safety, and the clinical endpoint still decide whether the design is useful.

Read any half-life claim with four qualifiers attached: exact chemical form, species, route, and measured endpoint. A rat intravenous concentration is not a human subcutaneous half-life. A downstream hormone remaining elevated is not necessarily the peptide remaining at the same concentration. Precision without those labels is mostly decorative.

Is CJC-1295 with DAC approved or banned in sport in 2026?

CJC-1295 with DAC is not an FDA-approved drug, and CJC-1295 is prohibited at all times for athletes under the 2026 World Anti-Doping Agency list. FDA’s current compounding-risk page says available clinical data are limited and identifies immunogenicity, impurity characterization, increased heart rate, and systemic vasodilatory reactions as concerns (FDA, current April 22, 2026).

The 2026 prohibited list places CJC-1295 among growth-hormone-releasing hormone analogues in S2.2.4, a category prohibited in and out of competition. Neither status answers whether DAC chemistry works; both answer what the label does not: a longer-lived research compound is still not an approved medicine or a permitted shortcut for a tested athlete.